Tumor localization strategies of multicancer early detection tests: a quantitative assessment
JNCI Cancer Spectrum · 03.03.2025 · 9 (2)
DOI: 10.1093/jncics/pkaf011 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 24.01.2025. Verfasst von Christopher Tyson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Exact Sciences Corporation, Madison, WI 53719, United States. Hauptthemen laut MEDLINE: Early Detection of Cancer, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Multicancer early detection tests may expand cancer screening. Characterizing diagnostic resolution approaches following positive multicancer early detection tests is critical. Two trials employed distinct resolution approaches: a molecular signal to predict tissue of origin and an imaging-based diagnostic strategy. This modeling study characterizes diagnostic journeys and impact in a hypothetical population of average-risk multicancer early detection–eligible patients.
Methods
A mathematical expression for diagnostic burden was derived using positive predictive value (PPV), molecular tissue of origin localization accuracy, and numbers of procedures associated with each diagnostic outcome. Imaging-based and molecular tissue of origin–informed strategies were compared. Excess lifetime cancer risk due to futile radiation exposure was estimated using organ-specific diagnostic imaging radiation doses.
Results
Across all PPVs and localization performances, a molecular tissue of origin strategy resulted in a higher diagnostic burden (mean = 3.6 [0.445] procedures vs mean = 2.6 [0.100] procedures) for the imaging strategy. Estimated diagnostic burden was higher for molecular tissue of origin in 95.5% of all PPV and tissue of origin accuracy combinations; at least 79% PPV and 90% accuracy would be required for a molecular tissue of origin–informed strategy to be less burdensome than imaging. The maximum rate of excess cancer incidence from radiation exposure for multicancer early detection false-positive results (individuals aged 50-84 years) was 64.6 of 100 000 (annual testing, 99% specificity), 48.5 of 100 000 (biennial testing, 98.5% specificity), and 64.6 of 100 000 (biennial testing, 98% specificity).
Conclusions
An imaging-based diagnostic strategy is more efficient than a molecular tissue of origin–informed approach across almost all PPV and tissue of origin accuracy combinations. The use of an imaging-based approach for cancer localization can be efficient and low-risk compared with a molecular-informed approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Exact Sciences Corporation, Madison, WI 53719, United States.
- Visionquest Development Partners, Atlanta, GA 30240, United States.
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, United States.
- Dana-Farber Cancer Institute, Harvard University, Boston, MA 02215, United States.
ORCID-Profile: Elliot K Fishman, Carlos Duran, Omair A Choudhry, Tomasz M Beer
Zitieren
APA
Tyson, C., Li, K. H., Cao, X., O'Brien, J. M., Fishman, E. K., O'Donnell, E. K., Duran, C., Parthasarathy, V., Rego, S. P., Choudhry, O. A., & Beer, T. M. (2025). Tumor localization strategies of multicancer early detection tests: a quantitative assessment. JNCI Cancer Spectrum, 9(2). https://doi.org/10.1093/jncics/pkaf011
Vancouver
Tyson C, Li KH, Cao X, O'Brien JM, Fishman EK, O'Donnell EK, et al. Tumor localization strategies of multicancer early detection tests: a quantitative assessment. JNCI Cancer Spectrum. 2025;9(2). doi:10.1093/jncics/pkaf011
BibTeX
@article{Tyson2025,
author = {Tyson, Christopher and Li, Kevin H and Cao, Xiting and O'Brien, James M and Fishman, Elliot K and O'Donnell, Elizabeth K and Duran, Carlos and Parthasarathy, Vijay and Rego, Seema P and Choudhry, Omair A and Beer, Tomasz M},
title = {Tumor localization strategies of multicancer early detection tests: a quantitative assessment},
journal = {JNCI Cancer Spectrum},
year = {2025},
volume = {9},
number = {2},
doi = {10.1093/jncics/pkaf011}
}
EUVIMED